Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients

Clinical Pharmacokinetics

Volumn 41, Issue 1, 2002, Pages 59-69

  Schädeli, Franziska ^a   Marti, Hans Peter ^a   Frey, Felix J ^a   Uehlinger, Dominik E ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN; CYCLOSPORIN A; PREDNISONE; CYCLOSPORINE;

AREA UNDER THE CURVE; ARTICLE; BIOLOGICAL MODEL; COVARIANCE; DOSE CALCULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; FEMALE; HEADACHE; HEARTBURN; HEAT SENSATION; HERPES LABIALIS; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MICROEMULSION; NAUSEA; NERVOUSNESS; PRIORITY JOURNAL; TREMOR; URTICARIA; VERTIGO; ABSORPTION LAG TIME; ABSORPTION RATE CONSTANT; ADULT; AGED; BLOOD SAMPLING; CENTRAL VOLUME OF DISTRIBUTION; COMPARTMENT MODEL; CREATININE BLOOD LEVEL; DIZZINESS; GRAFT RECIPIENT; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; MONOTHERAPY; ORAL ABSORPTION; PAIN; PLASMA CONCENTRATION-TIME CURVE; SIDE EFFECT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TROUGH CONCENTRATION;

EID: 0036174324     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241010-00005     Document Type: Article

References (36)

1. Optimizing the use of cyclosporine in renal transplantation
2. Challenges in cyclosporine therapy: The role of therapeutic monitoring by area under the curve monitoring
3. Trough levels and concentration time curves of cyclosporine in patients undergoing renal transplantation
4. Methods for clinical monitoring of cyclosporin in transplant patients
5. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection
6. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation
7. The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients
8. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group
9. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals
10. Influence of a fat-rich meal on the pharrnacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation
11. Bile-independent absorption of cyclosporine from a microemulsion formulation in liver transplant patients
12. Reversal of cyclosporine malabsorption in diabetic recipients of simultaneous pancreas and kidney transplant using a microemulsion formulation
13. Cyclosporine resorption in diabetic patients after simultaneous pancreas and kidney transplantation
14. Comparison of the absorption pharmacokinetics of Sandimmune and Neoral following porcine small bowel transplantation
15. A limited sampling strategy for the estimation of eight-hour Neoral areas under the curve in renal transplantation
16. Evaluation of instrumental, nonisotopic immunoassays (fluorescence polarization immunoassay and enzyme-multiplied immunoassay technique) for cyclosporine monitoring in whole blood after kidney and liver transplantation
17. Cyclosporine A monitoring in patients with renal, cardiac, and liver transplants: A comparison between fluorescence polarization immunoassay and two different RIA methods
18. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations
19. The NONMEM system
20. Cyclosporine pharmacokinetics and variability from a microemulsion formulation - A multicenter investigation in kidney transplant patients
21. A new microemulsion formulation of cyclosporin: Pharmacokinetic and clinical features
22. Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration
23. Abbreviated kinetic profiles to estimate exposure to CyA in renal allograft recipients treated with Sandimmun-Neoral
24. Abbreviating area under the curves further: A practical approach to monitoring extended pharmacokinetics with Neoral
25. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy
26. Estimated area-under-the-curve monitoring of Neoral in a stable pediatric renal transplant population: One-year experience
27. Comparison and validation of limited sampling equations for cyclosporine area-under-the-curve monitoring calculations in pediatric renal transplant recipients
28. Comparison of three methods for cyclosporine area under the curve monitoring calculations
29. Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate posttransplant period
30. Abbreviated cyclosporine AUCs on Neoral - The search continues!
31. Comparison of several approaches of therapeutic drug monitoring of cyclosporin A based on individual pharmacokinetics
32. Improving the therapeutic monitoring of cyclosporin A
33. Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy
34. Pharmacokinetic determinants of cyclosporin and prednisone in renal transplant patients